{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:21:42Z","timestamp":1794072102838,"version":"4.8.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T00:00:00Z","timestamp":1519603200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T00:00:00Z","timestamp":1519603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1111\/bjd.16270","type":"journal-article","created":{"date-parts":[[2017,12,24]],"date-time":"2017-12-24T10:54:22Z","timestamp":1514112862000},"page":"1199-1203","source":"Crossref","is-referenced-by-count":36,"title":["Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum"],"prefix":"10.1093","volume":"178","author":[{"given":"G.","family":"Salomon","sequence":"first","affiliation":[{"name":"Dermatology; Paul Sabatier-Toulouse III University; Institut Universitaire du Cancer de Toulouse; Toulouse France"},{"name":"CHU de Toulouse; Larrey Hospital; Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Maza","sequence":"additional","affiliation":[{"name":"Dermatology; Paul Sabatier-Toulouse III University; Institut Universitaire du Cancer de Toulouse; Toulouse France"},{"name":"CHU de Toulouse; Larrey Hospital; Toulouse France"},{"name":"Reference Center for Rare Skin Diseases; Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Boulinguez","sequence":"additional","affiliation":[{"name":"Dermatology; Paul Sabatier-Toulouse III University; Institut Universitaire du Cancer de Toulouse; Toulouse France"},{"name":"CHU de Toulouse; Larrey Hospital; Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0165-5263","authenticated-orcid":false,"given":"C.","family":"Paul","sequence":"additional","affiliation":[{"name":"Dermatology; Paul Sabatier-Toulouse III University; Institut Universitaire du Cancer de Toulouse; Toulouse France"},{"name":"CHU de Toulouse; Larrey Hospital; Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Lamant","sequence":"additional","affiliation":[{"name":"Pathology; University Cancer Institute of Toulouse; Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tournier","sequence":"additional","affiliation":[{"name":"Pathology; University Cancer Institute of Toulouse; Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mazereeuw-Hautier","sequence":"additional","affiliation":[{"name":"Dermatology; Paul Sabatier-Toulouse III University; Institut Universitaire du Cancer de Toulouse; Toulouse France"},{"name":"CHU de Toulouse; Larrey Hospital; Toulouse France"},{"name":"Reference Center for Rare Skin Diseases; Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4519-8666","authenticated-orcid":false,"given":"N.","family":"Meyer","sequence":"additional","affiliation":[{"name":"Dermatology; Paul Sabatier-Toulouse III University; Institut Universitaire du Cancer de Toulouse; Toulouse France"},{"name":"CHU de Toulouse; Larrey Hospital; Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,2,26]]},"reference":[{"key":"10.1111\/bjd.16270-BIB0001|bjd16270-cit-0001","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.dnarep.2008.01.014","article-title":"Incidence of DNA repair deficiency disorders in western Europe: Xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy","volume":"7","author":"Kleijer","year":"2008","journal-title":"DNA Repair"},{"key":"10.1111\/bjd.16270-BIB0002|bjd16270-cit-0002","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7326\/0003-4819-80-2-221","article-title":"Xeroderma pigmentosum an inherited diseases with sun sensitivity, multiple cutaneous neoplasms, and abnormal DNA repair","volume":"80","author":"Robbins","year":"1974","journal-title":"Ann Intern Med"},{"key":"10.1111\/bjd.16270-BIB0003|bjd16270-cit-0003","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/jmg.2010.083022","article-title":"Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterizes the role of DNA repair","volume":"48","author":"Bradford","year":"2011","journal-title":"J Med Genet"},{"key":"10.1111\/bjd.16270-BIB0004|bjd16270-cit-0004","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejca.2017.02.026","article-title":"Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab","volume":"77","author":"Hauschild","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1111\/bjd.16270-BIB0005|bjd16270-cit-0005","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/intimm\/dxh194","article-title":"PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells","volume":"17","author":"Iwai","year":"2005","journal-title":"Int Immunol"},{"key":"10.1111\/bjd.16270-BIB0006|bjd16270-cit-0006","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.16270-BIB0007|bjd16270-cit-0007","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1111\/bjd.16270-BIB0008|bjd16270-cit-0008","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1111\/bjd.16270-BIB0009|bjd16270-cit-0009","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1111\/bjd.16270-BIB0010|bjd16270-cit-0010","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"10.1111\/bjd.16270-BIB0011|bjd16270-cit-0011","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.dnarep.2011.03.005","article-title":"A new XPC gene splicing mutation has lead to the highest worldwide prevalence of xeroderma pigmentosum in black Mahori patients","volume":"10","author":"Cartault","year":"2011","journal-title":"DNA Repair"},{"key":"10.1111\/bjd.16270-BIB0012|bjd16270-cit-0012","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1200\/JCO.2016.68.1478","article-title":"Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort","volume":"32","author":"Chow","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.16270-BIB0013|bjd16270-cit-0013","first-page":"397","article-title":"Advances in the treatment of non-small cell lung cancer: focus on nivolumab, pembrolizumab, and atezolizumab","volume":"30","author":"Leventakos","year":"2016","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther"},{"key":"10.1111\/bjd.16270-BIB0014|bjd16270-cit-0014","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1039\/C2PP25267H","article-title":"Spotlight on \u2018xeroderma pigmentosum\u2019","volume":"12","author":"Fassihi","year":"2012","journal-title":"Photochem Photobiol Sci"},{"key":"10.1111\/bjd.16270-BIB0015|bjd16270-cit-0015","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.0022-202X.2005.23894.x","article-title":"Sunlight-induced immunosuppression in humans is initially because of UVB, then UVA, followed by interactive effects","volume":"125","author":"Poon","year":"2005","journal-title":"J Invest Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.16270","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.16270\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T13:38:40Z","timestamp":1676381920000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/178\/5\/1199\/6753009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,26]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.16270","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2,26]]}}}